Interestingly, in glioma patients treated with radiotherapy and TMZ, it was found that the simultaneous methylation of MGMT and KEAP1 promoters correlated with a lower risk of tumor progression, while patients showing methylated MGMT and unmethylated KEAP1 had a worse prognosis; this is in agreement with the fact that NRF2 activation confers protection to cancer cells against the genotoxic damage caused by chemotherapy and radiotherapy [48,49]. The gene discussed is NFE2L2; the disease is central nervous system cancer.